Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1955 1
1956 6
1957 7
1959 1
1960 2
1961 3
1962 1
1963 2
1964 1
1971 1
1972 2
1975 1
1976 3
1977 1
1978 1
1980 2
1981 2
1982 1
1983 3
1984 2
1985 3
1986 1
1987 2
1988 3
1990 2
1991 2
1992 10
1993 6
1994 9
1995 20
1996 25
1997 22
1998 32
1999 17
2000 22
2001 26
2002 15
2003 8
2004 8
2005 11
2006 17
2007 9
2008 12
2009 11
2010 13
2011 13
2012 15
2013 14
2014 18
2015 19
2016 31
2017 15
2018 23
2019 19
2020 14
2021 24
2022 26
2023 44
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

599 results

Results by year

Filters applied: . Clear all
Page 1
Neuromodulation for Cannabis Use: A Scoping Review.
Ngoy A, Tang VM, Xiao K, Blumberger DM, George TP, Gowin JL, Le Foll B, Sloan ME. Ngoy A, et al. Brain Sci. 2024 Apr 2;14(4):356. doi: 10.3390/brainsci14040356. Brain Sci. 2024. PMID: 38672008 Free PMC article. Review.
Catharanthine Modulates Mesolimbic Dopamine Transmission and Nicotine Psychomotor Effects via Inhibition of α6-Nicotinic Receptors and Dopamine Transporters.
Williams BM, Steed ND, Woolley JT, Moedl AA, Nelson CA, Jones GC, Burris MD, Arias HR, Kim OH, Jang EY, Hone AJ, McIntosh JM, Yorgason JT, Steffensen SC. Williams BM, et al. ACS Chem Neurosci. 2024 May 1;15(9):1738-1754. doi: 10.1021/acschemneuro.3c00478. Epub 2024 Apr 13. ACS Chem Neurosci. 2024. PMID: 38613458
Potential Serotonin 5-HT2A Receptor Agonist of Psychoactive Components of Silene undulata Aiton: LC-MS/MS, ADMET, and Molecular Docking Studies.
Alhawarri MB, Olimat S. Alhawarri MB, et al. Curr Pharm Biotechnol. 2024 Mar 29. doi: 10.2174/0113892010299804240324140017. Online ahead of print. Curr Pharm Biotechnol. 2024. PMID: 38561607
METHODS: LC-MS/MS analysis was conducted on S. undulata extract, identifying 51 phytochemicals, including norharman, harmalol, harmaline, harmine, and ibogaine alkaloids. ADMET and Molecular docking investigations were employed to assess the serotonergic potential of these …
METHODS: LC-MS/MS analysis was conducted on S. undulata extract, identifying 51 phytochemicals, including norharman, harmalol, harmaline, ha …
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.
Knuijver T, Ter Heine R, Schellekens AFA, Heydari P, Lucas L, Westra S, Belgers M, van Oosteren T, Verkes RJ, Kramers C. Knuijver T, et al. J Psychopharmacol. 2024 Mar 22:2698811241237873. doi: 10.1177/02698811241237873. Online ahead of print. J Psychopharmacol. 2024. PMID: 38519421 Free article.
They received a single dose of 10mg/kg ibogaine hydrochloride. Plasma PKs of ibogaine, noribogaine, and noribogaine glucuronide were obtained during 24 h. ...CONCLUSIONS: The clearance of ibogaine is strongly related to CYPD2D6 genotype. Ibogaine cardi …
They received a single dose of 10mg/kg ibogaine hydrochloride. Plasma PKs of ibogaine, noribogaine, and noribogaine glucuronid …
Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.
Cherian K, Shinozuka K, Tabaac BJ, Arenas A, Beutler BD, Evans VD, Fasano C, Muir OS. Cherian K, et al. Am J Ther. 2024 Mar-Apr 01;31(2):e133-e140. doi: 10.1097/MJT.0000000000001723. Am J Ther. 2024. PMID: 38518270
More RCTs with large sample sizes must be conducted to support ibogaine's safety and efficacy. CONCLUSIONS: Given the promising preliminary findings, ibogaine could potentially fill a much-needed gap in treatments for challenging conditions, including opioid …
More RCTs with large sample sizes must be conducted to support ibogaine's safety and efficacy. CONCLUSIONS: Given the promisin …
Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS. Tabaac BJ, et al. Am J Ther. 2024 Mar-Apr 01;31(2):e97-e103. doi: 10.1097/MJT.0000000000001727. Am J Ther. 2024. PMID: 38518266 Review.
The following series details the current state of research in psychedelic therapeutics, including lysergic acid diethylamide (LSD), N-N-dimethyltryptamine (DMT) and ayahuasca, psilocybin, ibogaine, MDMA, and ketamine. LIMITATIONS: While initial clinical trials of psychedel …
The following series details the current state of research in psychedelic therapeutics, including lysergic acid diethylamide (LSD), N-N-dime …
Noribogaine acute administration in rats promotes wakefulness and suppresses REM sleep.
Castro-Nin JP, Serantes D, Rodriguez P, Gonzalez B, Carrera I, Torterolo P, González J. Castro-Nin JP, et al. Psychopharmacology (Berl). 2024 Mar 12. doi: 10.1007/s00213-024-06572-2. Online ahead of print. Psychopharmacology (Berl). 2024. PMID: 38467891
Ibogaine is a potent atypical psychedelic that has gained considerable attention due to its antiaddictive and antidepressant properties in preclinical and clinical studies. Previous research from our group showed that ibogaine suppresses sleep and produces an altere
Ibogaine is a potent atypical psychedelic that has gained considerable attention due to its antiaddictive and antidepressant properti
599 results